C4 Therapeutics, Inc. Increase (Decrease) in Accounts Payable
C4 Therapeutics, Inc. (CCCC) reported Increase (Decrease) in Accounts Payable of $263.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- C4 Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $348.00K, a 77.31% decline year-over-year.
- C4 Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$85.00K.
- C4 Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$472.00K.
- C4 Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$885.00K, a 250.00% decline year-over-year.
- C4 Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$468.00K.
- C4 Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$119.00K, a 143.59% decline from fiscal 2023.
- C4 Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was $273.00K.
- C4 Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$3.33M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $348.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $263.00K 10-Q · filed 2026-08-11 | -$209.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.09M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$85.00K 10-Q · filed 2026-05-12 | -$557.00K derived: sum of 2 quarters · filed 2026-05-12 | -$1.44M derived: sum of 3 quarters · filed 2026-05-12 | $92.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$472.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.36M derived: sum of 2 quarters · filed 2026-02-26 | $177.00K derived: sum of 3 quarters · filed 2026-08-11 | -$468.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$885.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $649.00K derived: sum of 2 quarters · filed 2026-08-11 | $4.00K 10-Q · filed 2025-11-06 | -$172.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $889.00K 10-Q · filed 2026-08-11 | $713.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.30M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$645.00K 10-Q · filed 2026-05-12 | -$821.00K derived: sum of 2 quarters · filed 2026-05-12 | -$231.00K derived: sum of 3 quarters · filed 2026-05-12 | -$946.00K derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | -$176.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $414.00K derived: sum of 2 quarters · filed 2026-02-26 | -$301.00K derived: sum of 3 quarters · filed 2026-02-26 | -$119.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | $590.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$125.00K derived: sum of 2 quarters · filed 2025-11-06 | $57.00K 10-Q · filed 2025-11-06 | $226.00K derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$715.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$533.00K 10-Q · filed 2025-08-07 | -$364.00K derived: sum of 3 quarters · filed 2025-08-07 | -$1.20M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $182.00K 10-Q · filed 2025-05-07 | $351.00K derived: sum of 2 quarters · filed 2025-05-07 | -$486.00K derived: sum of 3 quarters · filed 2025-05-07 | $593.00K derived: sum of 4 quarters · filed 2025-05-07 | |
| 2023-12-31 | $169.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$668.00K derived: sum of 2 quarters · filed 2025-02-27 | $411.00K derived: sum of 3 quarters · filed 2025-02-27 | $273.00K 10-K · filed 2025-02-27 | |
| 2023-09-30 | -$837.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $242.00K derived: sum of 2 quarters · filed 2024-10-31 | $104.00K 10-Q · filed 2024-10-31 | -$972.00K derived: sum of 4 quarters · filed 2024-10-31 | |
| 2023-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $941.00K 10-Q · filed 2024-08-01 | -$135.00K derived: sum of 3 quarters · filed 2024-08-01 | -$1.83M derived: sum of 4 quarters · filed 2024-08-01 | |
| 2023-03-31 | -$138.00K 10-Q · filed 2024-05-08 | -$1.21M derived: sum of 2 quarters · filed 2024-05-08 | -$2.91M derived: sum of 3 quarters · filed 2024-05-08 | -$2.32M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | -$1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$2.77M derived: sum of 2 quarters · filed 2024-02-22 | -$2.18M derived: sum of 3 quarters · filed 2024-02-22 | -$3.33M 10-K · filed 2024-02-22 | |
| 2022-09-30 | -$1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$1.10M derived: sum of 2 quarters · filed 2023-11-01 | -$2.26M 10-Q · filed 2023-11-01 | -$1.50M derived: sum of 4 quarters · filed 2023-11-01 | |
| 2022-06-30 | $588.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$564.00K 10-Q · filed 2023-08-08 | $196.00K derived: sum of 3 quarters · filed 2023-08-08 | -$405.00K derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$1.15M 10-Q · filed 2023-05-04 | -$392.00K derived: sum of 2 quarters · filed 2023-05-04 | -$993.00K derived: sum of 3 quarters · filed 2023-05-04 | -$366.00K derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $760.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $159.00K derived: sum of 2 quarters · filed 2023-02-23 | $786.00K derived: sum of 3 quarters · filed 2023-02-23 | -$1.18M 10-K · filed 2023-02-23 | |
| 2021-09-30 | -$601.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $26.00K derived: sum of 2 quarters · filed 2022-11-03 | -$1.94M 10-Q · filed 2022-11-03 | -$1.34M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $627.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$1.34M 10-Q · filed 2022-08-04 | -$738.00K derived: sum of 3 quarters · filed 2022-08-04 | -$1.33M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$1.97M 10-Q · filed 2022-05-05 | -$1.36M derived: sum of 2 quarters · filed 2022-05-05 | -$1.96M derived: sum of 3 quarters · filed 2022-05-05 | $602.00K derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $5.00K derived: sum of 2 quarters · filed 2022-02-24 | $2.57M derived: sum of 3 quarters · filed 2022-02-24 | $467.00K 10-K · filed 2022-02-24 | |
| 2020-09-30 | -$595.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.97M derived: sum of 2 quarters · filed 2021-11-10 | -$133.00K 10-Q · filed 2021-11-10 | -$132.00K 10-Q · filed 2020-11-12 | $1.03M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $462.00K 10-Q · filed 2021-08-11 | $1.62M derived: sum of 3 quarters · filed 2022-02-24 | ||
| 2020-03-31 | -$2.10M 10-Q · filed 2021-05-13 | -$940.00K derived: sum of 2 quarters · filed 2022-02-24 | |||
| 2019-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $4.23M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $3.07M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |